China's BeiGene hands back rights to antibody-drug conjugate

13 November 2023
biotech_research_lab_big

Canadian biotech Zymeworks (TSX: ZYME) has reacquired rights for the antibody-drug conjugate (ADC) zanidatamab zovodotin, from partner BeiGene (Nasdaq: BGNE).

Zymeworks provided the update on the firms’ collaboration agreement as part of its financial results statement, with China-based BeiGene returning rights in the Asia–Pacific region.

The companies have been working together since November 2018, under the terms of a license and collaboration agreement for selected indications across multiple HER2-expressing cancers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology